Gaines v. AstraZeneca Pharmaceutical

Background

Ernest Edward Gaines sued AstraZeneca after receiving a payment from a 2012 settlement involving claims related to his use of Seroquel from December 21, 2005, through June 12, 2006. Gaines alleged that he was later diagnosed with diabetes and that the settlement did not provide enough compensation for his injury. He pointed to a reported average payment of $25,000, while he received $6,336.71 after attorney fees and costs were deducted from his $11,214.95 share.

Gaines proceeded without a lawyer and asked to amend his complaint several times. His third amended complaint named AstraZeneca as the sole defendant and asserted claims described as liability damages, breach of contract, fraudulent concealment, negligence, discovery, and a claim under Civil Rule 23. He sought more than $75,000 in damages.

Jurisdiction

The court explained that Gaines had not identified a federal law creating his claims or requiring resolution of a substantial federal question. It therefore found no basis for federal-question jurisdiction. The court determined that diversity jurisdiction appeared to exist because Gaines alleged that he was a Texas citizen, AstraZeneca was not a Texas citizen, and Gaines sought more than $75,000.

State-law claims and the settlement release

The court applied New York law because Gaines’s claims arose from litigation conducted in New York. Under that law, a settlement release generally remains effective unless a traditional ground for setting it aside—such as duress, illegality, fraud, or mutual mistake—is established.

The court rejected Gaines’s argument that receiving less than the average payout in other Seroquel cases justified additional compensation. An average payout does not mean every claimant was entitled to that amount, and Gaines’s allegations of being shorted were directed at attorneys who were not defendants in this action rather than at AstraZeneca.

The court also rejected his breach-of-contract theory. Although Gaines could be understood as alleging that he was a party to the 2012 settlement agreement, he did not allege that AstraZeneca failed to perform its obligations, failed to pay the amount required by the agreement, or promised additional payment for injuries that arose later.

The court found no mutual mistake. Gaines alleged that he and the attorneys representing him knew when the settlement was reached that he was pre-diabetic and had hypoglycemia. His later development of diabetes concerned the future course of a condition known at the time of settlement, which did not provide a basis for setting aside the release.

The court likewise found that Gaines alleged no facts showing that AstraZeneca concealed or misrepresented information to induce him to settle. His reference to fraudulent concealment was conclusory, and the court stated that his fraud claims also appeared to be time-barred. The court noted that the action was filed, at the earliest, in June 2021—years after the 2012 settlement payment and the 2014 diabetes diagnosis—and that Gaines had not identified a basis to extend the limitations period.

Disposition

The court dismissed the third amended complaint under 28 U.S.C. § 1915(e)(2)(B)(ii) for failure to state a claim. It declined to grant further leave to amend because Gaines had already received opportunities to amend and the complaint gave no indication that another amendment could cure the defects. The court certified that an appeal would not be taken in good faith, denied permission to appeal without paying filing fees, and directed the Clerk of Court to enter judgment.